GSK And HGS Face Off Over Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.